Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study
Xue‐Ning Yang, Hong‐Hong Yan, Jun Wang, Xiangyang Chu, Zhidong Liu, Yi Shen, Haitao Ma, Xiangning Fu, Jian Hu, Naikang Zhou, Yu Liu, Xinming Zhou, Jingsong Li, Kang Yang, Jian Li, Lin Xu, Siyu Wang, Qun Wang, Lunxu Liu, Shun Xu, Zhongyuan Chen, Hong-He Lou, Changli Wang, Ying Cheng, Si‐Yang Liu, Xu‐Chao Zhang, Wen‐Zhao Zhong, Yi‐Long Wu
Abstract
INTRODUCTION: mutation status and adjuvant chemotherapy treatment. METHODS: mutation status, and postoperative stage were analyzed post hoc. RESULTS: mutation status across all postoperative stages. CONCLUSIONS: mutation status and postoperative stage.
Topics & Concepts
MedicineInternal medicineConfidence intervalAdenocarcinomaOncologyCohortProportional hazards modelClinical endpointChemotherapyAdjuvantCancerClinical trialLung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies